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Abstract
Alterations in basal metabolic substrate preference were proposed as early
derangements in the development of skeletal muscle insulin resistance. Here, we
report that alterations in muscle substrate oxidation are not associated with muscle
insulin resistance in rats or humans. In this study we used a novel stable isotope
tracer ([U-13C]glucose) liquid chromatography-tandem mass spectrometry (LCMS/MS) method to measure the ratio of mitochondrial glucose oxidation by
pyruvate dehydrogenase flux (VPDH) relative to rates of citrate synthase flux (VCS)
in skeletal muscle. We found that high fat diet (HFD) fed insulin resistant rats did
not have altered substrate oxidation in soleus muscle in the fasting state.
Hyperinsulinemic-euglycemic clamps increased relative glucose oxidation in both
normal and insulin resistant rats, although this increase was blunted in HFD fed
insulin resistant rats, due to an impairment in insulin-stimulated muscle glucose
transport. Additionally, we found that an acute infusion of lipid during a
hyperinsulinemic-euglycemic

clamp

in

normal

rats

significantly

reduced

mitochondrial VPDH/VCS flux in soleus muscle without any effects on insulinstimulated peripheral glucose metabolism or muscle glucose transport. Using the
same stable isotope/LC-MS/MS approach we then examined VPDH/VCS flux in
insulin sensitive and insulin resistant humans and found similar relative rates of
VPDH/VCS following an overnight fast and similar increases in VPDH/VCS fluxes during
a hyperinsulinemic-euglycemic clamp. Taken together these results show that
basal mitochondrial substrate preference in muscle is not altered in insulin
resistant rats or insulin resistant humans and that acute modulation of substrate
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oxidation in normal rats does not affect muscle insulin sensitivity refuting the
metabolic inflexibility hypothesis which stipulates that alterations in substrate
oxidation as an essential step in the development of muscle insulin resistance.
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Introduction

I. Insulin Resistance and Type 2 Diabetes
Type 2 Diabetes (T2D) is emerging as a global epidemic, with the prevalence of
the disease increasing at a rate far exceeding previous predictions (1,2), with close
to 50 million people expected to live with T2D by the year 2030 (3). The age of
onset of T2D has inched earlier, and the prevalence of the disease has increased
among children and adolescents in recent years (4,5). These trends portend a
distressing future: the United States alone spent more than $170 billion in 2007 for
treatment of diabetes and its associated complications (6), and the disease is
expected to exact a heavy cost from economies around the world.
Despite the widespread and increasing prevalence of T2D and the
significant attention devoted to its study, the precise molecular mechanisms
leading to the development of T2D remain relatively poorly characterized. T2D can
be defined as the progressive development of insulin resistance accompanied by
the failure of insulin secretion that culminates in the clinical manifestation of
inappropriate fasting hyperglycemia. The exact sequence of these components –
as well as the relative importance of each – continues to be debated, but growing
evidence has pointed to the centrality of insulin resistance as the key event in the
pathogenesis of T2D (7–9). Impaired glucose disposal in response to insulin is
seen as one of the earliest defects in susceptible individuals (8–10). In fact, islet
cells increase insulin secretion in the early stages of diabetes during a period of
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compensated, subclinical insulin resistance (i.e. without overt hyperglycemia);
when β-cells are no longer able to compensate – either from the severity of insulin
resistance or due to a number of genetic factors that may predispose it to failure –
the patient manifests clinically with diabetes (11,12). Thus, understanding insulin
resistance and the precise molecular steps leading to its development is key to
understanding T2D and to developing potential therapies.
As master regulator of metabolism, insulin accomplishes a variety to key
tasks in disparate organ systems, which include 1) the suppression of lipolysis (or
the breakdown and release of fatty acids) in adipose tissue, 2) the shift from
gluconeogenesis to glycogen storage and lipogenesis in the liver, and 3) the
stimulation of glucose uptake and glycogen storage in skeletal muscle (7). These
varied effects ultimately converge to aid the body in the fasting to fed transition;
from the reliance on endogenous glucose production (performed by the liver and
crucial for obligate glucose utilizers like the brain) and fat/ketone oxidation (which
occurs in peripheral tissues like skeletal muscle) during times of nutrient
deprivation, to the storage and usage of exogenous glucose in times of nutrient
abundance (7,13). Insulin resistance, put simply, is the inability of insulin to
produce these effects in its target cells.
Skeletal muscle is a particularly important site of insulin action, as well as a
crucial player in the development of insulin resistance and T2D. For one, skeletal
muscle has a disproportionate influence on whole-body glucose homeostasis, as
it accounts for a major fraction of insulin-stimulated extrahepatic glucose uptake
(10). Furthermore, abnormalities in skeletal muscle – such as disordered nutrient
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storage, intramyocellular ectopic lipid accumulation, and associated impairments
in insulin-stimulated glucose uptake – have been observed in predisposed
individuals decades before the onset of frank T2D (8,14–16), suggesting that
derangements in skeletal muscle are some of the earliest to occur in the
pathogenesis of T2D, perhaps even earlier than dysfunctions in hepatic insulin
response. Third, exercise has been shown to stimulate glucose uptake in insulin
resistant muscle in an insulin-independent manner (17–19), emphasizing skeletal
muscle’s current and potential role (through both behavioral and pharmaceutical
approaches) in the treatment of T2D.
Despite intense study, the precise location of muscle insulin resistance –
that is, the molecular defect that prevents insulin from eliciting its normal
physiologic response in muscle – remains an unsolved mystery. Many of insulin’s
physiologic intracellular actions have been characterized: insulin’s binding to its
receptor sets off a cascade of events in the myocyte including heterodimerization
and autophosphorylation of the insulin receptor (a member of the tyrosine kinase
receptor family) and recruitment of key downstream mediators such as insulin
receptor substrate-1 (IRS-1), phosphoinositide-3 kinase (PI3K), and AKT. These
events ultimately serve to increase the translocation of the glucose transporter
GLUT4 to the membrane, increase glucose influx into the cell, increase the rate of
glycolysis, and increase glycogen synthesis (20–24). Many of these steps (as well
as other steps in insulin-independent pathways) have been implicated in the
development of muscle insulin resistance.
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II. Muscle Substrate Oxidation and the Metabolic Inflexibility Hypothesis
In this setting, alterations in mitochondrial substrate preference and oxidation have
been hypothesized as essential derangements in skeletal muscle insulin
resistance. Mitochondria are the site of oxidative disposal of acetyl-CoA, the end
product of both glycolysis and β-oxidation of fatty acids. In a seminal study
published more than 50 years ago, Randle et al. proposed that skeletal muscle
glucose and fat oxidation existed in competition within the myocyte and that
disordered oxidation of fat could in turn effect intracellular handling of glucose.
Based on a series of in vitro experiments in the rat heart, Randle observed that
increasing fat oxidation in the myocyte could directly inhibit glycolysis by increasing
the levels of key metabolites that could allosterically inhibit enzymes in the
glycolytic pathway, ultimately leading to the inhibition of glucose uptake in to the
cell. From these observations, Randle proposed that this intracellular glucose-fatty
acid cycle (nicknamed the “Randle cycle”) explains how 1) in normal individuals,
the physiologic increase in the availability of fatty acids in the fasting state leads to
an increase in fat oxidation and concomitant decrease in glucose oxidation in
myocytes and 2) in insulin resistant individuals, pathologically elevated fat
oxidation could inhibit glucose oxidation and, in turn, glucose uptake in myocytes
(25) (Graphic 1). The hypothesis notably did not require the implication of defects
in intracellular insulin signaling; increased fat oxidation (either directly through
altered mitochondrial preference, or indirectly through increased delivery of fatty
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acids to the myocyte) could reduce muscle glucose uptake regardless of changes
in insulin signaling. While Randle’s observations and predictions failed to be
confirmed in subsequent in vivo experiments, the ‘Randle cycle’ represented in its
time a novel and attractive explanation that connected mitochondrial substrate
handling and whole-body glucose homeostasis.
More recently and in a similar vein, the concept of ‘metabolic inflexibility’
has been proposed to cause muscle insulin resistance. The metabolic inflexibility
hypothesis, proposed by David Kelley, also placed disordered mitochondrial
substrate handling as the locus of insulin resistance, rather than defects in the
insulin signaling cascade. In his in vivo experiments in humans, Kelley used legspecific indirect calorimetry techniques1 to measure muscle substrate oxidation
and compare them between normal and insulin resistant subjects. Kelley found
that that while the muscles of normal individuals relied predominantly on fat
oxidation in the fasting state and on glucose oxidation in the insulin-stimulated
state, insulin resistant individuals 1) had paradoxically increased preference for
glucose oxidation in the fasting state and 2) could not modulate their muscle
substrate preference in response to insulin (26,27). Stated another way, insulin
resistant muscle seemed to be ‘locked in’ to a particular ratio of glucose to fat
oxidation and could not adjust its oxidative fuel based on physiological

1

Indirect calorimetry refers to the measurement of the arteriovenous differential in oxygen and
carbon dioxide content (in this case, across the leg) to approximate relative substrate oxidation in
myocytes. The technique centers on knowing the predicted stoichiometries of oxygen consumption
and carbon dioxide production for the oxidation of specific substrates (glucose, fat, ketone, amino
acid). In the case of humans in normal physiologic conditions, glucose and fatty acids were
assumed to be the major oxidative substrates in muscle.
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circumstance, fasting or fed. Kelley went on to conclude from these observations
that insulin resistance was a manifestation of underlying cellular ‘metabolic
inflexibility,’ or the inability to alter substrate oxidation in varying physiologic states:
metabolically inflexible myocytes operated at a saturated rate of glucose oxidation
that created an intracellular backlog unfavorable to further glucose uptake, even in
the setting of insulin (28). He further hypothesized that defects in the mitochondrial
enzymatic machinery that regulates both basal substrate metabolism and
transitions between glucose and fat oxidation were mechanistically responsible for
the onset of diabetes.
The concept of metabolic inflexibility has gained considerable traction in the
field of metabolism, and recent studies have proposed aberrations in pyruvate
dehydrogenase (PDH) (29), pyruvate dehydrogenase kinase (PDK) isoforms (30),
carnitine-palmitoyl transferase-1 (31), and carnitine acetyltransferase (CrAT) (32)
as possible mediators of altered basal substrate handling in insulin resistant
muscle and, therefore, as potential therapeutic targets in T2D.
(Continued on page 13)
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Graphic 1. A schematic of the proposed Randle cycle, which shows that increased fat oxidation results in an
increase in acetyl-CoA and citrate, which in turn inhibits key enzymes in the glycolysis pathway.

13

(Continued from page 11)

III. Problems with the Metabolic Inflexibility Hypothesis and Alternatives
Despite its widespread acceptance, whether metabolic inflexibility could explain
tissue-specific insulin resistance in vivo remains to be confirmed. In fact, the
indirect calorimetric technique employed in Kelley’s original studies have
significant

methodological

shortcomings

that

preclude

making

definitive

conclusions about tissue-specific substrate oxidation and changes therein. For
one, measurements of respiratory quotient using arterio-venous (A-V) respiratory
quotient (RQ) measurements across the leg were not truly muscle-specific but
reflect glucose and fat oxidation in additional tissues such as fat and bone. Further,
indirect calorimetry captures substrate disappearance from blood rather than true
cellular oxidation and does not account for interconversions between metabolic
substrates that occur in vivo and thus, is an imperfect measurement for true
substrate oxidation in the cell (33). To date, no conclusive evidence exists that
insulin resistant muscles have altered substrate preference in the fasting state and
that the blunting of insulin’s ability to increase muscle glucose oxidation is a result
of oxidative inflexibility rather than a primary defect in insulin-mediated glucose
transport.
In fact, evidence suggests that the defect in muscle insulin response in T2D
occurs at the level of insulin response, with impairments in the ability of insulin to
increase glucose transport across the membrane. A series of in vivo human
studies utilizing non-invasive magnetic resonance spectroscopy demonstrated that
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muscles of individuals had impaired glycogen synthesis not as a result of a
‘backlog’ and allosteric inhibition from disordered downstream oxidation, but from
a deficiency of substrate secondary to impaired insulin-stimulated GLUT4
translocation and defective glucose transport across the sarcolemma (34–37).
Furthermore, significant accumulation of ectopic intramyocellular lipid has been
observed in the early stages of insulin resistance in individuals susceptible to T2D;
subsequent experiments

showed that this ectopic lipid deposit increases

intracellular concentrations of bioactive lipid species such as diacylglycerols
(DAG), which in turn activates novel protein kinase C (PKC) isoforms that interfere
significantly with the intracellular insulin signaling transduction, particularly at the
level of insulin receptor substrate 1 (IRS1) (38–42). Taken together, these studies
suggest that, contrary to the metabolic inflexibility hypothesis, the primary
molecular insult in muscle insulin resistance is a proximal impairment in insulin
response and glucose transport secondary to excessive caloric intake and ectopic
lipid accumulation, rather than a backlog mechanism from a distal inflexibility in
mitochondrial substrate handling.

IV. Aims and Hypothesis
To directly assess the metabolic inflexibility hypothesis and avoid the limitations of
the A-V indirect calorimetry methodology we applied a novel combined stable
isotope tracer/LC-MS/MS approach to capture true muscle-specific substrate
oxidation and examine whether ‘metabolic inflexibility’ is operating in an in vivo
model of insulin resistance. By infusing [13C6] glucose and analyzing
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C
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enrichments of alanine and glutamate isotopologues in muscles, we measured
mitochondrial pyruvate dehydrogenase flux (VPDH) as a proportion of mitochondrial
citrate synthase flux (VCS), a highly sensitive and tissue-specific index for the
relative contribution of glucose oxidation to total mitochondrial oxidation
(VPDH/VCS). Using this method, we studied how induction of insulin resistance in
rats by high fat feeding affects substrate preference in the fasted state as well as
during a hyperinsulinemic-euglycemic clamp, which simulates the fed state. In
addition, we tested whether acute infusion of lipid during a hyperinsulinemiceuglycemic clamp, thus putting glucose and fatty acids in direct competition, in
normal rats could acutely modulate substrate oxidation in vivo and whether these
modulations in muscle oxidative substrate preference correlated with changes in
whole body insulin sensitivity.
We hypothesized that:
1. The major oxidative substrate during fasting is fat, not glucose.
2. Oxidative substrate preference in the fasting state in skeletal muscle is not
different between normal and insulin resistant subjects.
3. Insulin increases glucose transport, glycolytic flux, and glucose oxidation in
normal subjects. In insulin resistant subjects, the increase in glucose
oxidation is blunted.
4. Failure to increase glucose oxidation in response to insulin in insulinresistant subjects is due to impaired insulin-mediated glucose transport, not
due to metabolic inflexibility or due to defects in cellular oxidative
machinery.
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Methods
I. Experimental Design
The study design consisted of two rat populations, one fed regular chow and the
other fed four weeks of a high fat diet (HFD) that induces insulin resistance.
Surgical placement of arterial and venous catheters enabled infusions of various
tracers and bioactive agents in live, awake, and non-stressed rats, as well as
sampling of venous blood for the measurement of real-time concentrations of
metabolites. This design allowed us to study of dynamic changes in whole-body in
vivo metabolism rather than relying on in vitro or partial systems. Insulin
sensitivity/resistance was measured using hyperinsulinemic-euglycemic clamps,
in which a standardized rate of insulin and variable rates of glucose are infused
together in the rats to maintain euglycemia (~100 mg/dL) and the rate of glucose
required provides a quantitative index of the animal’s sensitivity to insulin. To study
muscle substrate oxidation, normal and HFD-fed rats were given a two-hour trace
infusion of glucose uniformly labeled with

13

C (i.e. all six of its carbons are

13

C);

the infusion of trace amounts ensured that the exogenous infusion of glucose did
not reflect a substantive increase in total substrate seen by the tissues of interest,
while the two-hour infusion time enabled the concentrations of tracer and its
downstream metabolites to reach steady state in blood and tissues. The infusions
of the glucose tracer were performed both after an overnight fast (which we
designated as the animal’s basal state), and concomitantly during a
hyperinsulinemic-euglycemic clamp (which simulated the hyperinsulinemic
conditions of the fed state). At the conclusion of the infusions, the rats were
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sacrificed and tissues of interest were quickly harvested and freeze-clamped in
liquid nitrogen to minimize post-mortem/ischemic changes.
In order to measure relative rates of glucose and fat oxidation in skeletal
muscle, tissue samples were analyzed for enrichments of in downstream
intracellular metabolites of the labeled glucose. Enrichment is defined as the
proportion of a labeled isotope to its native, non-labeled form. In the case of our
study, the infused glucose tracer mixes in blood with endogenous unlabeled
glucose, and the mixed pool of endogenous and isotopic glucose is taken up by
the myocyte. In the myocyte, the mixed glucose pool undergoes glycolysis and the
resulting acetyl-coA participates in the tricarboxylic acid cycle in mitochondria. The
downstream metabolites produced as a result of these intracellular glycolytic and
oxidative processes exist in mixed pools of native molecules and isotopes (i.e.
endogenous glucose will produce unlabeled acetyl-coA with glycolysis, while the
tracer will produce acetyl-coA with both of its carbons labeled with

13

C), and the

particular enrichments of each downstream metabolite depends on the starting
enrichment of the upstream substrate, as well as any subsequent dilutions from
endogenous metabolites contributed by other intracellular pathways. As an
example, the major processes that contribute to the intracellular acetyl-coA pool
include glycolysis, beta oxidation of lipids, and breakdown of ketones. While with
an infusion of glucose tracer glycolysis will increase the pool of labeled acetyl-coA,
any acetyl coA produced from beta oxidation or ketone oxidation will result in the
dilution of the enrichment of the intracellular acetyl-coA pool (Graphic 3). Insofar
as we can measure the enrichments of various metabolites and have a working
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model of the major cellular reactions contributing to the production, modification,
and degradation of these metabolites, we can relate the measured enrichments to
the rate of the reactions affecting them.
In a previous study, we showed that the using the ratio of measured
enrichments in select isotopes of alanine and glutamate in the tissues samples of
rats infused with labeled glucose tracer could be used to approximate the ratio of
in vivo glycolytic flux to the total oxidative flux (VPDH/VCS), or the relative
contribution of glucose oxidation to total oxidation in the myocyte (43).
Theoretically, calculating VPDH/VCS requires measurement of enrichments of
intracellular pyruvate and acetyl-coA, as the enzyme pyruvate dehydrogenase
converts pyruvate into acetyl-coA and is the final link between glycolysis and the
TCA cycle. In reality, intracellular pyruvate is difficult to measure consistently, while
intracellular acetyl-CoA is prone to rapid postmortem ischemic degradation.
Therefore, in conditions of steady state with infusion of our tracer, we assumed
that intracellular pyruvate enrichment equilibrates with the enrichment of alanine
(a related three-carbon molecule produced by the transfer of an amino group from
pyruvate), while the acetyl-coA enrichment equilibrates with α-ketoglutarate, which
in turn equilibrates with the enrichment of the glutamate pool (in particular,
glutamate enriched at the 4,5 carbon positions, the expected enrichment positions
of any

13

C contributed by the acetyl-coA derived from the infused tracer). Alanine

and glutamate form stable intracellular pools in steady state that can be measured
consistently and is relatively resistant to rapid postmortem changes (Graphic 4).
However, in order to definitively show that alanine and glutamate enrichments

19

would serve as appropriate surrogates for pyruvate and alanine, respectively, we
performed a series of validation experiments comparing the
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Graphic 3. A schematic demonstrating the conceptual basis for our tracer approach for determining tissuespecific substrate oxidation. The infused [13C6] glucose is taken up by the muscle cell, and the labeled carbons
assume predictable positions in downstream metabolites. The pool of labeled acetyl-coA from the glucose tracer
is diluted by contributions from beta oxidation of fatty acids, such that measurement of proportional labeling (i.e.
enrichment) of particular metabolites before and after this dilution can be used to determine relative glucose and
fat oxidation rates at the cellular level. The schematic also shows our assumption that pyruvate and αketoglutarate enrichments equilibrate with alanine and glutamate enrichments, respectively.

Graphic 4. In tissue samples, the ratio of measured glutamate (m+2) enrichment to alanine (m+3) enrichment
reflects the ratio of glucose oxidation to total mitochondrial oxidation (VPDH/VCS). A VPDH/VCS ratio of 0 results
from 100% fat oxidation relative to total oxidation, while a ratio of 1 suggests sole contribution of glucose
oxidation to total oxidation.
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enrichments of these pools in a variety of physiologic conditions, including fasting
and hyperinsulinemic states.
Using the above approach, we measured tissue-specific substrate oxidation
(i.e. VPDH/VCS) in skeletal muscle for both fast-twitch and slow-twitch skeletal
muscle. We studied how substrate oxidation changes compares between normal
and HFD-fed insulin resistant rats, during both fasting and fed-simulated (i.e.
hyperinsulinemic) conditions. To further test the validity of the metabolic inflexibility
hypothesis and to see whether there was metabolic ‘overload’ occurring in the
mitochondria in insulin resistant muscle, we measured levels of key oxidative
enzymes (pyruvate dehydrogenase, pyruvate dehydrogenase kinase, carnitine
palmitoyl transferase, and carnitine o-acetyl transferase) in tissues of both normal
and HFD-fed rats. To study the changes in insulin signaling with insulin resistance,
we measured levels and activities (as indicated by the proportion of
phosphorylated to total levels) of key enzymes in the insulin signaling cascade, as
well as concentrations of lipid species previously shown to interfere with insulin
signaling.
To study the effect of acute modulation of muscle substrate oxidation and
its relation to insulin resistance, we studied another cohort of normal rats and
compared them under two conditions, one during a hyperinsulinemic-euglycemic
clamp, the other during a co-infusion of non-esterified fatty acid during a
hyperinsulinemic-euglycemic clamp. Insulin is a powerful suppressor of
endogenous lipolysis; thus, the control group saw almost no fatty acid, while coinfusion of fatty acid during the clamp raised the level of plasma fatty acid to fasting
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levels and provide and increase fatty acid oxidation in skeletal muscle. As
previously with our comparison of normal and HFD-fed rats, we performed
infusions of uniformly-labeled glucose tracer, measured VPDH/VCS in skeletal
muscle samples, measured levels of key oxidative enzymes as well as
mitochondrial metabolites, and measured the phosphorylation of key enzymes in
the insulin signaling cascade.
Further information about the particular materials and specific protocols
used to undertake components of the above-mentioned overarching experimental
design are listed in detail below. Included at the conclusion of the methods section
is a statement about which components of the experiment were performed by the
author and which were performed by collaborating scientists.

II. Experimental Model And Subject Details
All animal studies were approved by the Yale University Institutional Animal Care
and Use Committee and were performed in accordance with all regulatory
standards. 250 g male Sprague-Dawley rats were obtained from Charles River
Laboratories (Wilmington, MA) and were group housed (3 per cage) while they
were fed either a high fat diet (Dyets #112245, Bethlehem, PA; 59% calories from
fat, 26% from carbohydrate, 15% from protein) or a chow diet (Harlan Teklad
#2018, Madison, WI; 18% calories from fat, 58% from carbohydrate, 24% from
protein), ad lib for 3 weeks. All rats then underwent surgery under general
isoflurane anesthesia for placement of polyethylene catheters in the common
carotid artery (PE50 tubing, Instech Solomon, Plymouth Meeting, PA) and the
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jugular vein (PE90 tubing, Instech), after which they were singly housed. The rats
were fed their respective diets ad lib for 1 more week, after which they were studied
and sacrificed. All in vivo studies were performed following an overnight (16 hr)
fast. At the conclusion of each study, rats were euthanized by IV pentobarbital.

III. Method Details
Animal Studies
In all studies, tracers were infused through a catheter placed ∼1 week prior in the
carotid artery, and blood was obtained from a catheter in the jugular vein. Unless
otherwise specified, all blood was drawn from the jugular vein. All studies began 1
hr after catheters were connected, reducing any impact of stress from handling on
the physiology assessed.

Flux Analysis
To measure VPDH/VCS flux in the basal fasted state, rats were infused with
[1,2,3,4,5,6-13C6]glucose (prime 3 mg/[kg-min] for 5 min, continuous infusion rate
1 mg/[kg-min]) for a total of 120 min, after which blood (600 µl whole blood) was
obtained from the venous catheter and immediately centrifuged and the plasma
obtained, and rats were sacrificed and their soleus and quadriceps muscles snapfrozen in situ using metal tongs pre-chilled in liquid N2. The VPDH/VCS flux was
measured as the ratio of [4,5-13C2]glutamate / [13C3]alanine in soleus and
quadriceps after a 2 hr infusion of [1,2,3,4,5,6-13C6]glucose (16.7 μmol/[kg-min]
prime for 5 min, 5.6 μmol/[kg-min] continuous infusion) based on the assumptions
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we have described previously (43–45). Alanine enrichment was measured by
GC/MS: samples were deprotonized with 5 volumes of methanol and derivatized
with 3 volumes of b-butanol 4N HCl, after which the samples were heated to 65°C
for 60 min, evaporated under N2 gas, and resuspended in 100 μL of trifluoroacetic
acid:methylene chloride (1:7). GC-MS was then used to determine the m+4 alanine
enrichment (retention time ∼4.1 min, m/z 242 [m0], 243 [m+1], 244 [m+2], 245
[m+3], 246 [m+4]). Glutamate enrichment was measured by LC-MS/MS: the
samples were homogenized in 500 μL ice-cold methanol using a TissueLyser and
filtered through a Nanosep filter. LC-MS/MS (AbSCIEX 6500 QTRAP with a
Shimadzu ultrafast liquid chromatography system, negative ion mode) was used
to monitor the relevant ion pairs: [m0] C4-5 glutamate, 146/41, [m+1] C4-5
glutamate, 147/47, and [m+2] C4-5 glutamate, 148/48.
To measure muscle glucose uptake, a bolus of [6,6-14C]2-deoxyglucose
was administered in all rats. The harvested soleus and quadriceps muscles were
processed to determine glucose uptake in both tissues by comparing the plasma
[14C] specific activity decay curve to tissue [14C] specific activity, both measured
using a scintillation counter (46).

Hyperinsulinemic Glucose Clamps
Rats were given a 40 mU/kg bolus of Regular insulin followed by a 2 hr insulin
infusion at a rate of 4.0 mU/(kg-min), while euglycemia was maintained with
variable infusion of [1,2,3,4,5,6-13C6]glucose. Blood samples were drawn from the
venous catheter at 0, 15, 30, 45, 60, 70, 80, 90, 100, 120 min of the clamp, with
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the samples from the 120 min time point used to measure clamp glucose turnover.
Plasma insulin was measured by radioimmunoassay by the Yale Diabetes
Research Center at the 0 and 120min time points of the clamp. Glucose turnover
+,-./, /1,2.34/15

in the clamp was calculated as above 𝑇𝑢𝑟𝑛𝑜𝑣𝑒𝑟 = *67-84- /1,2.34/15 − 1; ∗
𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑒, and the rate of whole-body glucose disposal was calculated as the

sum of the glucose infusion rate plus the glucose turnover rate measured in the
clamp.

For combined lipid infusion and hyperinsulinemic-euglycemic clamps, rats were
infused with Intralipid 20% emulsion (Baxter Inc.) at the rate 40 µL/[kg-min] in
addition to variable infusions of [1,2,3,4,5,6-13C6]glucose tracer for 2 hours. Plasma
samples from 0 and 120 min time points for 2 hr lipid infusions were used to
measure plasma non-esterified fatty acid levels with the method described below.

Biochemical Analysis
Plasma glucose concentrations were measured enzymatically using the YSI
Glucose Analyzer (Yellow Springs, OH). Plasma NEFA concentrations were
measured spectrophotometrically using a Wako reagent (Wako Diagnostics,
Mountain View, CA).

Tissue Analysis
Muscle DAG and ceramide concentrations (40), acetyl- and malonyl-CoA (47,48)
were measured as we have described. Muscle PKCq membrane/cytosol ratio (49),
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insulin receptor phosphorylation relative to total insulin receptor, and Akt
phosphorylation relative to total Akt were measured by Western blot using
antibodies from Cell Signaling. PDH phosphorylation relative to total PDH was
measured by Western blot using antibodies from Calbiochem (pPDH s300, s232,
s293) and Abcam (PDH). Glucose-6-phosphate concentrations were measured
using an enzymatic assay from Sigma-Aldrich. Pyruvate concentrations were
measured using GC/MS after derivatization with o-phenylene-diamine (SigmaAldrich) dissolved in 4M HCl, extraction with ethyl acetate, and further
derivatization of the dried organic layer with a 1:1 BSTFA (Sigma-Aldrich) and
pyridine (Sigma-Aldrich) mixture. Concentrations of TCA cycle intermediates
(citrate, malate, succinate) were measured as reported previously (45). IRS-1associated PI3-kinase activity was measured as reported previously (40). CPT1b
was measured using antibodies from Santa Cruz. CrAT was measured using
antibodies from ProteinTech. PDH, CPT1b, and CrAT levels were normalized to
GAPDH levels, which was measured with antibodies from Cell Signaling. Muscle
concentrations of G-6-P, pyruvate, acetyl-CoA, malonyl-CoA, and TCA cycle
intermediates were measured in tissues freeze-clamped in situ to minimize
changes due to post-mortem ischemia.

IV. Quantification And Statistical Analysis
Comparisons were performed using the 2-tailed Student’s t-test, unpaired unless
otherwise specified in the figure legends, with significance defined as a p-value
<0.05. GraphPad Prism 7.0 (San Diego, CA) was used for all statistical analysis.
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In most cases, n=8-10 rats per group, unless otherwise indicated in the figure
legends. Data are presented as the mean±S.E.M.

V. Contributions
All animal experiments were designed/conducted and all data were analyzed
independently by the author during the 2017-2018 academic year, with financial
support from the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), under the guidance of Dr. Gerald I. Shulman, Dr. Gary Cline, and Dr. Kitt
F. Petersen. Preliminary experiments demonstrating the feasibility of using
uniformly-labeled glucose tracer for the study of tissue-specific VPDH/VCS were
performed by Tiago Alves, a former graduate student in the Shulman lab. The
author learned how to perform clamps and tracer infusion experiments under the
tutelage of Rachel Perry, a former postdoctoral fellow in the Shuman lab. Rachel
Perry and graduate students Alexander Munk and Ye Zhang provided technical
assistance during clamp and infusion experiments.
The following contributions were from staff scientists in the Shulman lab.
Gina Butrico and Xian-Man Zhang provided assistance with the use of mass
spectrometry (both liquid and gas chromatography) for the measurement of
intracellular metabolite concentrations and their enrichments. Mario Kahn provided
assistance with measurement of intramyocellular lipid species. Dongyan Zhang
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instructed the author on western blot technique and assisted with the PI3K assay.
Jianying Dong performed all of the surgeries on rats.

29

Results
In comparison to normal chow fed rats, rats fed 4 weeks of a high fat diet (HFD)
exhibited increased body weight (Fig. S1A) and became insulin resistant, as
manifested by higher plasma insulin levels required to maintain the same level of
plasma glucose in the fasting state (Fig. S1B, D) as well as by reduced glucose
infusion rate required to maintain euglycemia during a hyperinsulinemiceuglycemic clamp (Fig. S1G). Furthermore, insulin-stimulated muscle glucose
uptake (Rd) and muscle glucose transport, as measured by radioactive 2deoxyglucose uptake, were significantly impaired during the clamp (Fig. 1A-B),
confirming the presence of skeletal muscle insulin resistance in these rats.
To test whether the metabolic inflexibility hypothesis could explain the
development of muscle insulin resistance in these HFD-fed rats, we sought to
study whether the HFD-fed rats had altered oxidative substrate preference in
skeletal muscle in the basal state. We used [13C6] glucose as a tracer during the
clamp and used tissue-specific enrichments of alanine and glutamate to measure
in vivo VPDH/VCS in soleus and quadriceps muscles (43). As mentioned in the
methods section, although calculation of true VPDH/VCS requires the comparison of
intracellular pyruvate and acetyl CoA enriched by the [13C6] glucose tracer, these
metabolites undergo rapid ex vivo degradation and are difficult to measure. Under
conditions of steady state, intracellular pyruvate [m+3] was assumed to equilibrate
with alanine [m+3], and acetyl CoA [m+2] was assumed to equilibrate with C4C5
glutamate [m+2]. Both alanine and glutamate are more stable ex vivo relative to
their respective counterparts and were more amenable to reliable and consistent
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measurement of their intracellular enrichments. A rigorous comparison study of the
enrichments of these metabolites (performed in rat tissues freeze-clamped in situ
to minimize ischemic degradation) showed significant and near 1:1 correlations
between alanine and pyruvate enrichments as well as between C4C5 glutamate
and acetyl CoA enrichments under a variety of experimental conditions (Fig. S3AB), validating our equilibration assumptions and indicating that alanine and C4C5
glutamate enrichments could be reliably used to approximate in vivo VPDH/VCS.
Using this approach, we found that, contrary to what Kelley et al. had
observed in humans using, A-V indirect calorimetry, skeletal muscles of normal
rats relied predominantly (>90%) on fat oxidation in the fasting state (Fig. 1C-F)
(27,50). Furthermore, in contrast to what the metabolic flexibility hypothesis would
predict, we found that this overwhelming preference for fat oxidation in both soleus
and quad muscle during the fasting state did not change in insulin resistant HFDrats (Fig. 1C-F). In response to insulin during a clamp, normal rats upregulated
relative glucose oxidation in soleus muscle to ~50% and in quad muscles, which
contain a lower proportion of slow twitch (oxidative) to fast twitch (glycolytic) fibers,
to ~25% (Fig. 1C-F). In HFD-fed rats, however, this increase in glucose oxidation
in response to insulin was blunted in both skeletal muscles (Fig. 1C-F). These
results indicated that insulin resistance in the HFD-fed rats was characterized not
by alterations in basal substrate use but by a defect in their ability to increase
glucose oxidation in the presence of insulin.
This impairment in the ability of HFD-fed rats to increase glucose oxidation
with insulin could have resulted either from a defect in the mitochondrial oxidative
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capacity or from limited substrate availability secondary to a defect in insulinmediated glucose transport. To see which was operating in our rat model of insulin
resistance, we measured basal levels of key oxidative enzymes and found that
there were no differences in the expression of PDH, CPT1b (the isoform of CPT
predominant in skeletal muscle), and CrAT, a regulator of the mitochondrial acetylCoA pool that was suggested as a candidate for altered substrate handling in the
metabolic inflexibility hypothesis of insulin resistance (Fig. 2C). Furthermore, we
found no difference in the phosphorylation of PDH in both fasting and clamped
states between the two groups, suggesting that HFD-fed rats did not have impaired
activity of PDH and capacity to oxidize glucose (Fig. 2A). Finally, muscle
concentrations of tricarboxylic acid cycle metabolites were not altered with HFD
(Fig. 2B), making it unlikely that the mitochondria of insulin resistant rats had
‘metabolic overload’ that might impede smooth transitions between fat and glucose
oxidation. All in all, we did not find evidence that the mitochondria of HFD-fed rats
acquired defects in mitochondrial oxidative capacity that could explain the
impairments in insulin-stimulated glucose oxidation we observed in skeletal
muscle. To test whether impairments in glucose transport could provide an
alternative explanation, we measured previously reported mediators of ectopic
lipid-induced blockage of insulin signaling and found that HFD-fed rats displayed
increased baseline translocation of protein kinase Cq (PKCq) and impaired
phosphorylation of AKT in response to insulin (Fig. 2D,F). Furthermore, HFD-fed
rats showed significantly reduced insulin receptor substrate-1 (IRS-1)-associated
phosphoinositide 3-kinase (PI3-K) activity, a proximate and sensitive indicator of
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insulin-stimulated glucose transport (Fig. 2E). Altogether, these results support the
hypothesis that the major defect in the early stages of the pathogenesis of muscle
insulin resistance is ectopic lipid-induced blockage in insulin-mediated glucose
transport due to proximal defects in insulin signaling, rather than acquired
‘metabolic inflexibility.’
Given that insulin resistant rats fed HFD failed to display alterations in basal
substrate use, we wanted to see if acute modulation of intramyocellular substrate
oxidation

in

normal

rats

could

influence

muscle

insulin

response.

Hyperinsulinemic-euglycemic clamps suppressed fasting white adipocyte tissue
(WAT) lipolysis as exhibited by reductions in non-esterified fatty acid (NEFA) from
~1.0 mM to ~0.2 mM, but concomitant infusion of intralipid during a clamp raised
NEFA back to approximately fasting plasma concentrations (~1.2 mM) (Fig. S2F).
Providing NEFA in competition with glucose led to significant reductions (~50%) in
relative glucose oxidation in both soleus and quadriceps as measured by VPDH/VCS
(Fig. 3C-D), which occurred independently of changes in phosphorylation of PDH
(Fig. S2H). Interestingly, infusion of intralipid increased intramyocellular acetylCoA and glutamate concentrations but not glucose-6-phosphate or citrate
concentrations (Fig. 3F). This constellation of changes in intracellular metabolites
with increased fat oxidation is consistent with acetyl-CoA-mediated allosteric
inhibition of PDH activity, but not with Randle’s proposed mechanism of fat
oxidation-induced inhibition of key glycolytic steps and glucose uptake, which
predicts increases in glucose-6-phosphate and citrate concentrations with
increased fat oxidation (25,51). Furthermore, we found that the significant
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reduction in muscle glucose oxidation seen in the intralipid group was not
accompanied by any changes in measures of in vivo muscle insulin response such
as whole-body glucose uptake, muscle glucose transport, and muscle AKT
phosphorylation (Fig. 3A-B, E), dissociating alterations in substrate oxidation from
skeletal muscle insulin sensitivity.
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Figure 2
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Supplementary Figure 1
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Supplementary Figure 3
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Discussion
The precise mechanism leading to the development of muscle insulin resistance
has not yet been defined, but alterations in mitochondrial substrate preference has
emerged as an attractive possibility. Randle was the first to hypothesize a path by
which altered muscle substrate use, namely, increased muscle mitochondrial fatty
acid oxidation, could inhibit not only glucose oxidation but glucose uptake in
response to insulin (25,51). More recently as an expansion or update of Randle’s
proposals, others have suggested that muscle insulin resistance is a result of
‘metabolic inflexibility,’ or muscle mitochondrial dysfunction that results in
impairments in its ability to make smooth transitions between utilizing glucose or
fatty acids as substrates depending on varying physiological needs. These
hypotheses have located mitochondrial fuel preference as the nexus of muscle
insulin resistance, in contrast to competing hypotheses that centered on defects in
insulin signaling and insulin-mediated glucose transport. ‘Metabolic inflexibility’
necessarily entails two predictions about insulin resistant muscle: first, that fasting
or basal substrate preference is altered in insulin resistant muscle due to
mitochondrial dysfunction; and second, that insulin resistant muscle cannot
increase glucose oxidation beyond its basal rate as a result of this mitochondrial
dysfunction (26,27). In this hypothesis, the accumulation of intramyocellular lipid
observed in insulin resistant muscle is hypothesized to be secondary to an
impaired mitochondrial ability to oxidize fat, in opposition to other hypotheses that
have proposed that the buildup of certain lipid metabolites (diacylglycerols,
ceramides, etc.) lead to inhibition of insulin signaling.
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While ‘metabolic inflexibility’ has become a widespread concept, the original
studies by Kelley had significant methodological shortcomings that leave the
precise relationship between muscle substrate oxidation and muscle insulin
response hitherto unresolved (26,27) Furthermore, subsequent studies by other
groups to identify possible candidate defects for muscle ‘metabolic inflexibility’
have predominantly relied on in vitro models or genetic manipulations to show
altered mitochondrial substrate preference and oxidation. In this study, we used
HFD-fed rats who were at the early stages of muscle insulin resistance to
characterize early myocellular changes that mechanistically contributed to the
development of this phenomenon. Importantly, by infusing a stable isotope tracer
([13C6]glucose) and analyzing enrichments in particular isotopologues of
intramyocellular metabolites by LC-MS/MS, we were able to obtain a sensitive
measure for muscle-specific glucose oxidation relative to total mitochondrial
oxidation and relate this measure to in vivo indices of muscle insulin resistance in
normal and HFD-fed rats as well as insulin sensitive and insulin resistant humans.
With these methods, we sought to adjudicate between two competing hypotheses
for the pathogenesis of muscle insulin resistance: one in which mitochondrial
derangements lead to altered substrate preference and prevent insulin-mediated
glucose uptake by a backlog mechanism; and two in which excess ectopic lipid
build-up leads to interference with insulin signaling and prevents insulin-mediated
glucose transport.
Our results contradict the predictions of the ‘metabolic inflexibility’
hypothesis in three major ways. First, while Kelley et al. had observed relative
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glucose oxidation in normal fasting muscle contributed a significant proportion of
total oxidation at 40% (27), we found relative glucose oxidation normal fasting
muscle to be minimal at less than 10% in both soleus (primarily type I oxidative
fibers) and quadriceps (primarily type II glycolytic fibers) (52). Second, while the
‘metabolic inflexibility’ hypothesis predicts that fasting substrate use in insulin
resistant muscle would be significantly altered in favor of increased glucose
oxidation, we found that the fasting muscles of insulin resistant rats did not differ
from muscles of normal rats in their substrate preference and also relied
overwhelmingly on fat oxidation (Fig. 1C-F). This lack of altered fasting substrate
preference was corroborated by the absence of significant changes in muscle
mitochondrial oxidative function and capacity in insulin resistant rats, as indicated
by unchanged expressions of key mitochondrial oxidative enzymes such as PDH,
CPT1b, and CrAT (Fig. 2C), and by unchanged concentrations of mitochondrial
TCA cycle metabolites (Fig. 2B). Finally, whereas Kelley et al. had observed that
insulin resistant muscle could not upregulate relative glucose oxidation in response
to insulin (i.e. were metabolically inflexible), we found that muscles of insulin
resistant rats increased relative glucose oxidation with insulin (i.e. were
metabolically flexible), though the increase was blunted compared to normal
muscle (Fig. 1C-F).

This blunting of increased glucose oxidation was likely

secondary to defects in insulin signaling (Fig. 2E) and insulin-mediated glucose
transport (Fig. 2B, D, F) in insulin resistant rats. Taken together these data
demonstrate that the muscles of insulin resistant rats were in fact metabolically
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flexible but that this metabolic flexibility was constrained by defects in insulinmediated glucose transport.
If muscle insulin resistance is not characterized by alterations in muscle
substrate use, we asked conversely whether modulations in muscle substrate use
in normal rats could affect insulin sensitivity. We found that changes in muscle
substrate oxidation were dissociated from muscle insulin response. Infusion of
intralipid in normal rats during a hyperinsulinemic-euglycemic clamp raised plasma
fatty acid levels and significantly reduced glucose oxidation in muscle, but did not
alter muscle glucose uptake, muscle glucose transport, or muscle insulin signaling
(Fig. 3A-E). Furthermore, we did not find evidence for Randle’s proposed glucosefatty acid cycle in which increased fatty acid oxidation in the myocyte could inhibit
glucose oxidation and glucose uptake through inhibition of key regulated steps in
glycolysis. While Randle had observed in in vitro studies that increased fat
oxidation led to increased levels of acetyl CoA, citrate, and glucose-6-phosphate,
we found that only acetyl CoA concentrations were increased in vivo (Fig. 3F),
suggesting that fatty acid oxidation could inhibit glucose oxidation through
allosteric inhibition of PDH (and not through inhibition of key glycolytic steps) but
that this reduced PDH flux was ultimately inconsequential in the larger picture of
muscle insulin response. Together with a recent study which found the
complementary result that acutely increasing PDH flux with dichloroacetate did not
affect muscle insulin sensitivity (53), these data dissociate changes in substrate
oxidation from muscle insulin sensitivity and suggest that attempts to develop
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therapeutics to treat insulin resistance and type 2 diabetes by targeting
mitochondrial substrate preference would likely prove ineffective.
Though we do not find evidence of ‘metabolic inflexibility’ in the
pathogenesis of muscle insulin resistance nor of any mechanistic relationship
between modulation of mitochondrial substrate preference and muscle insulin
sensitivity, these data should not be taken as evidence that mitochondrial
dysfunction more broadly is insignificant to the development of metabolic disease.
In fact, robust evidence exists that reductions in mitochondrial function may be an
important predisposing contributor to myocellular lipid accumulation and muscle
insulin resistance in the lean offspring of parent with type 2 diabetics (54–56) and
the elderly (57). These effects, however, could be attributed to reductions in total
mitochondrial energy expenditure leading to increased ectopic lipid accumulation
and not to specific alterations in substrate utilization. Consistent with overall
reductions in skeletal muscle mitochondrial function as previously documented by
both in vivo
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P magnetic resonance spectroscopy (MRS) (56) and

13

C MRS (54)

we also observed a reduction in insulin-stimulated muscle mitochondrial VCS flux
in the insulin resistant subjects as assess by in vivo 13C MRS. Thus, it is important
to distinguish mitochondrial substrate preference per se, which these data
demonstrate has little impact on the development of muscle insulin resistance,
from reductions in overall mitochondrial function and fat oxidation that leads to the
imbalance of energy intake and expenditure, ectopic lipid build-up, and insulin
resistance. In support of this hypothesis Knowles et al. have recently identified a
gene variant in N-acetyl transferase-2 (Nat2) in humans that is associated with
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T2DM (58). Nat1 (mouse homologue) knockout mice display reduced whole-body
energy metabolism (58,59), reduced mitochondrial function, increased ectopic lipid
deposition and liver and muscle insulin resistance (59).
In summary, these studies demonstrate that in contrast to the tenets of the
metabolic flexibility hypothesis there are no alterations in basal rates of
mitochondrial VPDH/VCS flux in insulin resistant human or rodent skeletal muscle
thus providing strong evidence against hypotheses that relate alterations in muscle
substrate preference to muscle insulin resistance.
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